Table 11.
Duration/dose of SAP used in primary TKA as reported by 5 of 16 participating registries (n = 341,177 TKAs). Values are count (%)
| Factor | DKR | KP | NAR | PABZ | SAR |
|---|---|---|---|---|---|
| Primary TKAs | 49,377 | 123,418 | 40,709 | 4,544 | 123,129 |
| TKAs with no SAP | 40 (0.1) | 16,368 (13) | 0 | 111 (2.4) | 6 (0.0) |
| Duration/dose | |||||
| 1 day 1 dose a | 3,858 (7.8) | 30,971 (25) | 1,831 (4.3) | 4,433 (98) | 788 (0.6) |
| 1 day 2 doses | 60,877 (50) | 1,412 (3.5) | 3,681 (3.0) | ||
| 1 day 3 doses | 7,098 (5.8) | 2,060 (5.1) | 97,251(79) | ||
| 1 day 4 doses | 2,065 (1.7) | 33,597 (83) | 17,874 (15) | ||
| 1 day > 1 dose | 29,961 (62) | ||||
| 2 days | 5,386 (4.4) | 959 (0.8) | |||
| 2 days or more | 544 (1.1) | ||||
| 3 days | 223 (0.2) | 354 (0.3) | |||
| Others b | 416 (0.3) | 391 (0.3) | |||
| Unknown | 14,974 (30) | 14 (0.0) | 1,809 (4.4) | 1,825 (1.6) | |
a
Preoperatively
b
Includes 1-day ≥ 5 doses; SAP administered over ≥ 4 days.